Publicaciones en colaboración con investigadores/as de University of Bologna (18)

2023

  1. Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma: final analysis of KEYNOTE-170

    Blood, Vol. 142, Núm. 2, pp. 141-145

2022

  1. Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma

    Blood Advances

2019

  1. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

    The Lancet, Vol. 393, Núm. 10168, pp. 229-240

  2. Pembrolizumab in relapsed or refractory primary mediastinal large b-cell lymphoma

    Journal of Clinical Oncology

  3. Randomized phase III study of alisertib or investigator’s choice (selected single agent) in patients with relapsed or refractory peripheral T-cell lymphoma ¨

    Journal of Clinical Oncology

2018

  1. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial

    The Lancet Oncology, Vol. 19, Núm. 9, pp. 1192-1204

2017

  1. Is good clinical practice becoming poor clinical care?

    HemaSphere

  2. Long-term survival of patients with CLL after allogeneic transplantation: A report from the European Society for Blood and Marrow Transplantation

    Bone Marrow Transplantation, Vol. 52, Núm. 3, pp. 372-380

2016

  1. European phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed/refractory peripheral T-cell lymphoma

    Haematologica

2015

  1. Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-Cell non-hodgkin lymphoma: Final analysis of the GAUSS study

    Journal of Clinical Oncology

2014

  1. Intraclonal heterogeneity is a critical early event in the development of myeloma and precedes the development of clinical symptoms

    Leukemia, Vol. 28, Núm. 2, pp. 384-390

  2. Therapeutic options in relapsed or refractory peripheral T-cell lymphoma

    Cancer Treatment Reviews, Vol. 40, Núm. 9, pp. 1080-1088

2012

  1. Bortezomib plus rituximab versus rituximab in patients with high-risk, relapsed, rituximab-naïve or rituximab-sensitive follicular lymphoma: Subgroup analysis of a randomized phase 3 trial

    Journal of Hematology and Oncology, Vol. 5

  2. High-Dose Therapy and Autologous Stem Cell Transplantation in First Relapse for Diffuse Large B Cell Lymphoma in the Rituximab Era: An Analysis Based on Data from the European Blood and Marrow Transplantation Registry

    Biology of Blood and Marrow Transplantation, Vol. 18, Núm. 5, pp. 788-793

2009

  1. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: Identification of prognostic factors predicting outcome

    Haematologica, Vol. 94, Núm. 2, pp. 230-238

2007

  1. A phase II multicenter study of troxacitabine in relapsed or refractory lymphoproliferative neoplasms or multiple myeloma

    Leukemia and Lymphoma, Vol. 48, Núm. 1, pp. 39-45

2003

  1. Marrow versus peripheral blood for geno-identical allogeneic stem cell transplantation in acute myelocytic leukemia: Influence of dose and stem cell source shows better outcome with rich marrow

    Blood, Vol. 102, Núm. 8, pp. 3043-3051

2002

  1. Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia

    Blood, Vol. 100, Núm. 12, pp. 3877-3886